A multi-parameter response prediction model for rituximab in rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Joint, bone, spine : revue du rhumatisme

• Publication date

  2017-03-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jbspin.2017.02.015PMID 28363827
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Newcastle University

  2019cited by this paper
• A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus

  2016cited by this paper
• Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment

  2016cited by this paper
• A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study

  2016cited by this paper
• Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy.

  2015cited by this paper
• Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab

  2015cited by this paper
• Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

  2015cited by this paper
• Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome‐Wide DNA Microarray

  2014cited by this paper
• Use of Whole‐Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open‐Label Trial

  2014cited by this paper
• High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis.

  2014cited by this paper
• Longterm Effects of Rituximab on B Cell Counts and Autoantibody Production in Rheumatoid Arthritis: Use of High-sensitivity Flow Cytometry for More Sensitive Assessment of B Cell Depletion

  2013cited by this paper
• Development and Validation of a New Disease Activity Score in 28 Joints–Based Treatment Response Criterion for Rheumatoid Arthritis

  2013cited by this paper
• CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.

  2013cited by this paper
• Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial

  2013cited by this paper
• Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis.

  2013cited by this paper
• B lymphocyte-typing for prediction of clinical response to rituximab

  2012cited by this paper
• The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

  2012cited by this paper
• Maternal smoking during pregnancy and offspring growth in childhood: 1993 and 2004 Pelotas cohort studies

  2011cited by this paper
• Importance of Correlation between Gene Expression Levels: Application to the Type I Interferon Signature in Rheumatoid Arthritis

  2011cited by this paper
• New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine.

  2011cited by this paper
• Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.

  2011cited by this paper
• B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.

  2011cited by this paper
• Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

  2010cited by this paper
• Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.

  2010cited by this paper
• Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.

  2010cited by this paper
• Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.

  2010cited by this paper
• Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab

  2010cited by this paper
• Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis

  2009cited by this paper
• Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor ( TNF ) agents after previous failure of an anti-TNF agent ?

  2009cited by this paper
• Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

  2009cited by this paper
• Cells of the synovium in rheumatoid arthritis. B cells

  2007cited by this paper
• Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients

  2007cited by this paper
• The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

  2006cited by this paper
• Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

  2006cited by this paper
• Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.

  2004cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6.

  2003cited by this paper
• Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.

  2003cited by this paper
• Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.

  2003cited by this paper
• Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

  2001cited by this paper
• T Cell Activation in Rheumatoid Synovium Is B Cell Dependent1

  2001cited by this paper

• Mechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases

  2024cites this paper
• High-Titer Rheumatoid Factor is Associated with Worse Clinical Outcomes and Higher Needs for Advanced Therapies in Rheumatoid Arthritis Under Real-Life Conditions

  2024cites this paper
• Role of IFN-α in Rheumatoid Arthritis

  2023cites this paper
• Clinical prediction models of rheumatoid arthritis and its complications: focus on cardiovascular disease and interstitial lung disease

  2023cites this paper
• Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming

  2022cites this paper
• Predictors of response of rituximab in rheumatoid arthritis by weighted gene co-expression network analysis

  2022cites this paper
• A case-control study

  2021cites this paper
• Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial

  2021cites this paper
• The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease.

  2021cites this paper
• Toward Overcoming Treatment Failure in Rheumatoid Arthritis

  2021cites this paper
• Establishment of A Clinical Diagnostic Model for Gouty Arthritis Based on Serum Biochemical Profile: A Prospective Study

  2020cites this paper
• The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery

  2020cites this paper
• Predictors of treatment response in rheumatoid arthritis.

  2019cites this paper
• Facteurs prédictifs de réponses dans la polyarthrite rhumatoïde

  2019cites this paper
• FRI0083 IS A HIGH LEVEL OF IGA PREDICTIVE OF THE EFFICACY AND TOLERANCE OF RITUXIMAB DURING RHEUMATOID ARTHRITIS NAIVE OF PRIOR BIOLOGICAL TREATMENTS?

  2019cites this paper
• A comprehensive review of rituximab therapy in rheumatoid arthritis patients

  2019cites this paper
• FRI0082 EFFECTIVENESS OF TNF INHIBITORS VS. NON-TNF INHIBITORS (ABATACEPT, TOCILIZUMAB AND RITUXIMAB) AFTER FAILURE OF NON-TNFI BIOLOGIC DMARD IN RHEUMATOID ARTHRITIS –COLLABORATION BETWEEN FIVE NATIONAL REGISTERS

  2019cites this paper
• IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis

  2019cites this paper
• Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As a Clinical Biomarker

  2018cites this paper
• Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature

  2018cites this paper
• Genotypes, phenotypes and treatment with immunomodulators in the rheumatic diseases

  2018cites this paper
• Interferon-α -mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming

  year unknowncites this paper